Strand Therapeutics

As a therapeutics company, being patient centric and focused is our #1 mission and priority. Looking forward to continuing to advance our programs and help patient lives across the globe – starting with cancer! #mRNA #patients #BioTech

We’re honored to announce the appointment of Jason Luke, MD, FACP, FASCO, as Strand Therapeutics' Chief Medical Officer. A respected clinician-researcher and professor at the University of Pittsburgh Medical Center specializing in cancer immunotherapy, Dr. Luke will oversee Strand’s clinical development strategy, pipeline advancement, and medical affairs. Welcome to the team!

We’re pioneering the future of mRNA cancer therapies. Our genetic circuits are designed to activate treatments only where they’re needed: inside the tumor. Our goal is to drive greater precision and safety while bringing revolutionary outcomes for patients.  Watch our new explainer video to see how it works.  #mRNA #CancerResearch #SyntheticBiology #StrandTherapeutics

Nasdaq helped us in celebrating our Series B with a billboard in the heart of Time Square! Thank you to our friends at Nasdaq for your support on our mission to create cures for patients!

Thank you to the NYSE for celebrating our Series B news with us last week! #Strand #SeriesB #NYSE

🚀 We’re proud to announce Strand Therapeutics has closed a $153M Series B financing round. This milestone enables us to accelerate the development of our programmable mRNA therapeutics and expand clinical efforts across oncology and beyond. We’re grateful to our new and existing investors for their belief in our mission to transform medicine through synthetic biology and mRNA engineering. The future of biology is programmable: and it’s here. #Biotech #mRNA #SyntheticBiology #StrandTherapeutics #SeriesB #PrecisionMedicine https://lnkd.in/exbwTHMH

We're thrilled to have been named one of Boston Business Journal's 2025 Best Places to Work — the BBJ’s exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people!  #BBJ #BPTW #BPTW2025 #BiotechNews #Biotech #mRNAResearch #mRNA #mRNATherapies

We are proud to announce our initial first-in-human phase 1 data for STX-001. Our ongoing clinical trial, conducted in a monotherapy setting, has demonstrated favorable safety and tolerability, with promising early activity in patients with advanced solid tumors.   STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment.   Join us at ASCO for more information: Abstract Title: Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors. Session Type: Poster Date and Time: June 1, 9:00 AM-12:00 PM CDT Abstract Number: 9556 Location: Hall A Full abstract is available on the ASCO Annual Meeting Website. Read our press release: https://lnkd.in/eJwN_KRq

Come by our abstract presentation tomorrow at #ASGCT2025 to learn about the groundbreaking data from the preclinical program for STX-003 -- a systemically delivered self-replicating mRNA encoding IL-12. STX-003 bears programmable genetic circuitry to limit the expression of payload in off-target tissues while preserving expression in the tumor. Session Details: Abstract Title: STX-003: A mRNA Cancer Immunotherapy Utilizing Cancer-Selective Programmable Genetic Circuits for Systemic Tumor Control Session Type: Oral Session Title: Targeted Gene and Cell Therapy for Cancer Date and Time: May 17, 8:15-8:30 am CT Abstract Number: 394 Location: Room 291-292 Full abstract is available on the ASGCT Annual Meeting website. https://lnkd.in/dHgkVjV #BiotechNews #Biotech #mRNAResearch #mRNA #mRNATherapies

Come by our poster presentation today at #ASGCT2025 to learn about exciting ongoing work for our STX-005 program! Session Details: Abstract Title: Long-acting circular RNA CAR drives potent and durable tumor elimination in vivo Session Type: Poster Session Title: Tuesday Poster Reception Date and Time: May 13, 6:00-7:30 pm CT Abstract Number: 781 Location: Hall I1-I2 Full abstract is available on the ASGCT Annual Meeting website. https://lnkd.in/dHgkVjV #BiotechNews #Biotech #mRNAResearch #mRNA #mRNATherapies